secwatch.observer — SEC 8-K summary
======================================

Issuer:     BeOne Medicines Ltd. (ONC)
CIK:        0001651308
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001651308-24-000118
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BeiGene appoints Shalini Sharp to Board of Directors effective September 27, 2024
--------------------------------------------------------------------------------

- Shalini Sharp, aged 49, appointed to fill vacancy on board expanded to 12 members.
- Former CFO of Ultragenyx Pharmaceuticals (2012-2020) and board member of Neurocrine Biosciences and Organon.
- Will receive equity awards valued at $400,000, annual cash compensation of $65,000 plus $17,500 for Audit Committee service.
- Appointment effective September 27, 2024; she will serve as Class III director until 2025 annual meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000118/0001651308-24-000118-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1651308/000165130824000118/bgne-20240925.htm
  HTML page:      https://secwatch.observer/filing/0001651308-24-000118

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer